Trials / Recruiting
RecruitingNCT07063342
A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC Reference Following Single Doses, and to Explore the Effect of Food After Multiple Doses of Selected Prototypes in Healthy Adult Participants
Phase 1, 3-Part, Open-label Study to Evaluate the Pharmacokinetics of Novel KarX (BMS-986519) and KarT (BMS-986520) Prototypes Versus the KarXT (BMS-986510) and KarX-EC (BMS-986519) Reference Following Single Doses, and to Explore the Effect of Food After Multiple Doses of Selected Prototypes in Healthy Adult Participants
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 72 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate novel KarX and KarT prototypes versus the KarXT and KarX-EC reference following single doses, and to explore the effect of food after multiple doses of selected prototypes in healthy adult participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Xanomeline/Trospium Chloride Capsule | Specified dose on specified days |
| DRUG | Xanomeline Enteric Capsule | Specified dose on specified days |
| DRUG | Trospium Chloride | Specified dose on specified days |
Timeline
- Start date
- 2025-06-27
- Primary completion
- 2026-08-15
- Completion
- 2026-08-15
- First posted
- 2025-07-14
- Last updated
- 2025-12-19
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT07063342. Inclusion in this directory is not an endorsement.